No, 12 Gy in 6 fractions is NOT the standard dose for prophylactic cranial irradiation in acute lymphoblastic leukemia.
For CNS-3 disease (overt CNS leukemia) at diagnosis in ALL, the standard dose is 18 Gy at 1.5-1.8 Gy per fraction, not 12 Gy in 6 fractions 1, 2.
Standard Dosing for ALL
The NCCN guidelines clearly specify that:
- CNS-3 disease at diagnosis: 18 Gy cranial irradiation is the standard therapeutic dose 1
- Fractionation: 1.5-1.8 Gy per fraction is recommended 2
- This translates to approximately 10-12 fractions total, not 6 fractions
The 2025 NCCN Pediatric ALL guidelines explicitly state: "If cranial radiation is done, recommended dosing is 18 Gy at 1.5–1.8 Gy/fraction" 2.
Why 12 Gy in 6 Fractions is Inappropriate
The 12 Gy dose you're asking about represents:
- Subtherapeutic dosing for CNS leukemia treatment
- A dose that was historically used in older protocols but has been abandoned
- Insufficient biological equivalent dose for disease control in ALL
Historical data from the 1980s-1990s showed that reduced doses (12-15 Gy) were associated with higher CNS relapse rates, which is why 18 Gy became standard 3, 4.
Context from Emergency Guidelines
The ILROG COVID-19 emergency guidelines mention 12 Gy in 3 fractions (4 Gy per fraction) for myeloid sarcoma/leukemia with focal leptomeningeal spine disease, but this is:
- For a different disease entity (myeloid, not lymphoblastic)
- For palliative/emergency situations during resource shortage
- Not applicable to standard ALL management 5
Current Treatment Paradigm
The modern approach prioritizes avoiding cranial radiation entirely when possible 1, 2, 6:
- Most patients receive CNS prophylaxis through intensive intrathecal chemotherapy (methotrexate alone or triple therapy with cytarabine and corticosteroids)
- High-dose systemic chemotherapy (methotrexate, cytarabine) that penetrates the blood-brain barrier
- Cranial radiation is reserved for CNS-3 disease at diagnosis or CNS relapse
The 2026 ASH guidelines for AYA ALL suggest against routine cranial radiation for CNS prophylaxis in patients on pediatric-inspired (asparaginase-containing) regimens 6.
Critical Caveat
If you're considering any dose reduction or alternative fractionation, this must be done only within the context of a specific treatment protocol that has been validated for efficacy. The recommended radiation dose is highly dependent on the intensity of concurrent systemic and intrathecal chemotherapy 1. Deviating from established protocols risks treatment failure and CNS relapse, which carries significant morbidity and mortality.